These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1180 related articles for article (PubMed ID: 17588900)

  • 1. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.
    Outeiro TF; Kontopoulos E; Altmann SM; Kufareva I; Strathearn KE; Amore AM; Volk CB; Maxwell MM; Rochet JC; McLean PJ; Young AB; Abagyan R; Feany MB; Hyman BT; Kazantsev AG
    Science; 2007 Jul; 317(5837):516-9. PubMed ID: 17588900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linking SIRT2 to Parkinson's disease.
    Garske AL; Smith BC; Denu JM
    ACS Chem Biol; 2007 Aug; 2(8):529-32. PubMed ID: 17708669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicine. The yin-yang of sirtuins.
    Dillin A; Kelly JW
    Science; 2007 Jul; 317(5837):461-2. PubMed ID: 17656709
    [No Abstract]   [Full Text] [Related]  

  • 4. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.
    Kontopoulos E; Parvin JD; Feany MB
    Hum Mol Genet; 2006 Oct; 15(20):3012-23. PubMed ID: 16959795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression.
    Liu P; Wang X; Gao N; Zhu H; Dai X; Xu Y; Ma C; Huang L; Liu Y; Qin C
    Brain Res; 2010 Jan; 1307():134-41. PubMed ID: 19852948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
    Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
    Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
    Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
    J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
    Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
    Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Embryonic stem cell-derived neuron models of Parkinson's disease exhibit delayed neuronal death.
    Yamashita H; Nakamura T; Takahashi T; Nagano Y; Hiji M; Hirabayashi T; Amano T; Yagi T; Sakai N; Kohriyama T; Matsumoto M
    J Neurochem; 2006 Jul; 98(1):45-56. PubMed ID: 16805795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
    Jiang H; Wu YC; Nakamura M; Liang Y; Tanaka Y; Holmes S; Dawson VL; Dawson TM; Ross CA; Smith WW
    Neurobiol Aging; 2007 Nov; 28(11):1709-17. PubMed ID: 16978743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
    Park SS; Schulz EM; Lee D
    Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammalian Sir2-related protein (SIRT) 2-mediated modulation of resistance to axonal degeneration in slow Wallerian degeneration mice: a crucial role of tubulin deacetylation.
    Suzuki K; Koike T
    Neuroscience; 2007 Jul; 147(3):599-612. PubMed ID: 17574768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi.
    Sapru MK; Yates JW; Hogan S; Jiang L; Halter J; Bohn MC
    Exp Neurol; 2006 Apr; 198(2):382-90. PubMed ID: 16455076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.
    Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P
    Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirtuin inhibitors.
    Alcaín FJ; Villalba JM
    Expert Opin Ther Pat; 2009 Mar; 19(3):283-94. PubMed ID: 19441904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetylation of Sirt2 by p300 attenuates its deacetylase activity.
    Han Y; Jin YH; Kim YJ; Kang BY; Choi HJ; Kim DW; Yeo CY; Lee KY
    Biochem Biophys Res Commun; 2008 Oct; 375(4):576-80. PubMed ID: 18722353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caenorhabditis elegans as a model system for identifying effectors of α-synuclein misfolding and dopaminergic cell death associated with Parkinson's disease.
    Harrington AJ; Knight AL; Caldwell GA; Caldwell KA
    Methods; 2011 Mar; 53(3):220-5. PubMed ID: 21195766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors that target tubulin.
    Schemies J; Sippl W; Jung M
    Cancer Lett; 2009 Aug; 280(2):222-32. PubMed ID: 19268440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition.
    Harrison IF; Smith AD; Dexter DT
    Neurosci Lett; 2018 Feb; 666():48-57. PubMed ID: 29273397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.